![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Clinical Investigator Gets FDA Warning Letter for Protocol Deviations
Clinical Investigator Gets FDA Warning Letter for Protocol Deviations
![](https://www.fdanews.com/ext/resources/images/Marketing_Images/archives/d/DrugSafetyPills.gif?t=1471301313&width=817)
August 15, 2016
The FDA is faulting a clinical investigator for neglecting to follow the established procedures for a trial testing a new investigational drug.
An FDA warning letter states that North Hill Medical Research’s clinical investigator John Gabriel failed to adhere to an FDA-approved protocol for the trial.
Agency investigators said that Gabriel randomized patients in a clinical trial without verifying that they met the inclusion criteria, which included taking a recent sample of patients’ serum creatinine — a waste product in the blood that comes from muscle activity — and an estimate of their glomerular filtration rate.
Upcoming Events
-
21Oct